| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early dise...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Curr...
Guardant Health, Inc. ("Guardant Health") (NASDAQ:GH), a leading precision oncology company, today announced its intent...
Guardant Health, Inc. ("Guardant Health") (NASDAQ:GH), a leading precision oncology company, today announced the commen...
Top weekly large-cap gainers included Teradyne, Wayfair, Illumina, Guardant Health, ASE, C.H. Robinson, Lumen, Symbotic, Credo,...
UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $80 to $110.
Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $65 to ...